Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (171-180 of 743) with videos related to

Pageof 75
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|March 25, 2020
Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for ImmunotherapyEvan T Hall, Elena Fernandez-Lopez, Ann W Silk, et al.
Journal of Cutaneous Pathology|July 2, 2003
Hepatitis C and G viruses in B-cell lymphomas of the skinSonja Michaelis, Dmitry V Kazakov, Mirka Schmid, et al.
Blood|June 18, 2005
Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cellsLucie Heinzerling, Valerie Künzi, Patrick A Oberholzer, et al.
European Journal of Dermatology : EJD|April 29, 2010
Melanoma after laser therapy of pigmented lesions--circumstances and outcomeMarie C Zipser, Joanna Mangana, Patrick A Oberholzer, et al.
Journal for Immunotherapy of Cancer|October 10, 2020
Evolving impact of long-term survival results on metastatic melanoma treatmentOlivier Michielin, Michael B Atkins, Henry B Koon, et al.
The Journal of Investigative Dermatology|July 25, 2017
HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma PatientsYoshihiro Ishida, Atsushi Otsuka, Hidenori Tanaka, et al.
Oncoimmunology|September 19, 2017
MEK inhibition and immune responses in advanced melanomaReinhard Dummer, Egle Ramelyte, Sabrina Schindler, et al.
Dermatology (Basel, Switzerland)|September 12, 2019
Dapsone in a Large Tertiary Center: Outdated Therapeutic Option or Timeless Agent?Florian Anzengruber, Janina Schenk, Vanessa Graf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Proliferation of CD30+ T-helper 2 lymphoma cells can be inhibited by CD30 receptor cross-linking with recombinant CD30 ligandJörg Willers, Reinhard Dummer, Werner Kempf, et al.
The Journal of Investigative Dermatology|December 14, 2011
Cutaneous lymphomas: molecular pathways leading to new drugsReinhard Dummer, Simone M Goldinger, Antonio Cozzio, et al.
Pageof 75

Showing results (171-180 of 743) with videos related to

Sort By:
Pageof 75
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|March 25, 2020
Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for ImmunotherapyEvan T Hall, Elena Fernandez-Lopez, Ann W Silk, et al.
Journal of Cutaneous Pathology|July 2, 2003
Hepatitis C and G viruses in B-cell lymphomas of the skinSonja Michaelis, Dmitry V Kazakov, Mirka Schmid, et al.
Blood|June 18, 2005
Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cellsLucie Heinzerling, Valerie Künzi, Patrick A Oberholzer, et al.
European Journal of Dermatology : EJD|April 29, 2010
Melanoma after laser therapy of pigmented lesions--circumstances and outcomeMarie C Zipser, Joanna Mangana, Patrick A Oberholzer, et al.
Journal for Immunotherapy of Cancer|October 10, 2020
Evolving impact of long-term survival results on metastatic melanoma treatmentOlivier Michielin, Michael B Atkins, Henry B Koon, et al.
The Journal of Investigative Dermatology|July 25, 2017
HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma PatientsYoshihiro Ishida, Atsushi Otsuka, Hidenori Tanaka, et al.
Oncoimmunology|September 19, 2017
MEK inhibition and immune responses in advanced melanomaReinhard Dummer, Egle Ramelyte, Sabrina Schindler, et al.
Dermatology (Basel, Switzerland)|September 12, 2019
Dapsone in a Large Tertiary Center: Outdated Therapeutic Option or Timeless Agent?Florian Anzengruber, Janina Schenk, Vanessa Graf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Proliferation of CD30+ T-helper 2 lymphoma cells can be inhibited by CD30 receptor cross-linking with recombinant CD30 ligandJörg Willers, Reinhard Dummer, Werner Kempf, et al.
The Journal of Investigative Dermatology|December 14, 2011
Cutaneous lymphomas: molecular pathways leading to new drugsReinhard Dummer, Simone M Goldinger, Antonio Cozzio, et al.
Pageof 75